Risks of Polypharmacy in Older Adults and Strategies for Prescription Optimization

Risks of Polypharmacy in Older Adults and Strategies for Prescription Optimization

Polypharmacy—commonly defined as the concurrent use of five or more medications—has become a widespread issue among older adults, largely driven by the high prevalence of multimorbidity in this population[1][2][3]. While some degree of polypharmacy may be clinically appropriate, the risks often outweigh the benefits when medication regimens become unnecessarily complex or include potentially inappropriate medications (PIMs)[4][5][2][6].

---

1. Risks of Polypharmacy in Older Adults

1.1 Adverse Drug Events (ADEs) and Drug–Drug Interactions

With advancing age, physiological changes such as reduced renal and hepatic function, altered pharmacokinetics, and increased pharmacodynamic sensitivity heighten older adults' vulnerability to ADEs[4][7]. The risk of ADEs rises exponentially as the number of medications increases, particularly with polypharmacy (≥5 drugs) and hyperpolypharmacy (≥10 drugs)[1][2][3]. These risks include not only drug–drug interactions but also drug–disease and drug–nutrient interactions[4][5][7].

1.2 Cognitive Impairment and CNS Effects

Polypharmacy frequently involves CNS-active medications—including antidepressants, antipsychotics, antiepileptics, benzodiazepines, and opioids—which carry an increased risk of cognitive impairment, delirium, and sedation[8][9][10]. For instance, 13.9% of community-dwelling older adults with dementia in the US are exposed to CNS-active polypharmacy, with prolonged exposure linked to higher rates of cognitive decline and fall-related injury[8].

1.3 Functional Decline, Falls, and Frailty

Polypharmacy, especially involving drugs with CNS activity or those impacting blood pressure, substantially elevates the risk of falls and subsequent functional decline in the elderly[11][12]. Notably, the fall risk is particularly accentuated when the regimen includes at least one medication known to increase fall risk (e.g., CNS drugs, diuretics)[11]. Furthermore, longitudinal studies have shown a bidirectional relationship between polypharmacy and frailty in community-dwelling older adults, suggesting that polypharmacy can contribute to the onset and progression of frailty[12][7].

1.4 Hospitalization, Mortality, and Healthcare Utilization

Research consistently demonstrates that polypharmacy is associated with increased rates of hospitalization, emergency department visits, mortality, and higher healthcare costs[4][5][13][3]. An integrated review found polypharmacy to be a significant predictor of hospitalization, nursing home placement, death, hypoglycemia, fractures, impaired mobility, pneumonia, and malnutrition[13].

1.5 Non-Adherence and Prescribing Cascades

Complex medication regimens contribute to decreased adherence, driven by confusion, cognitive challenges, and pill burden[5][7][14]. Polypharmacy also increases the risk of "prescribing cascades," where the adverse effects of one drug are misinterpreted as a new medical condition, prompting further prescriptions and compounding the risk of ADEs[9][6][5].

1.6 Sociodemographic and System-Level Determinants

Risk factors for polypharmacy include advanced age, higher comorbidity burden, poor self-perceived health, low socioeconomic status, and increased healthcare utilization. System-level factors—such as fragmented care, uncoordinated prescribing by multiple providers, and poorly maintained medication records—further exacerbate inappropriate polypharmacy[1][15][7][3].

---

2. Strategies for Prescription Optimization

Given the complex risks, targeted interventions are essential to optimize prescribing in older adults. Evidence suggests a multicomponent, multidisciplinary approach is most effective[16][5][17].

2.1 Medication Review and Deprescribing

Structured medication reviews, particularly those involving pharmacists, are central to identifying and discontinuing unnecessary or harmful medications (deprescribing)[17][16][5]. A widely cited deprescribing protocol includes five steps: identifying all medications, assessing risk of harm, evaluating benefit–harm ratio for each drug, prioritizing drugs for discontinuation, and implementing/monitoring a discontinuation plan[17][16]. However, challenges exist—such as prescriber inertia and patient resistance—which can be mitigated by involving patients in shared decision-making[14][18]. Family conferences and interdisciplinary discussions can facilitate acceptance of deprescribing, although sustainable clinical benefits require ongoing efforts[18].

Recent randomized trials indicate that pharmacist-led interventions for deprescribing have variable effects. For example, targeted deprescribing of anticholinergic and sedative medications among frail older adults did not produce significant reduction in drug burden within six months, highlighting barriers to effective deprescribing and implementation fidelity[10].

2.2 Use of Screening Tools

Several explicit and implicit tools guide appropriate prescribing in older adults. These include:

• Beers Criteria: List of potentially inappropriate medications for older adults.
• STOPP/START Criteria: Explicit indicators for potentially inappropriate medications (STOPP) and recommended therapies (START)[16][5][2][9].
• Medication Appropriateness Index (MAI): Implicit tool for medication review.

No single tool is universally superior; rather, combining tools and integrating them into computerized clinical decision support systems can improve their utility and impact[16][2][9].

2.3 Interdisciplinary Team-Based Care

Involving geriatricians, pharmacists, nurses, and primary care physicians in medication management yields better identification and resolution of polypharmacy challenges[16][5][17]. Team-based models of care reduce the prevalence of inappropriate prescribing and improve the quality of medication use.

2.4 Patient and Caregiver Engagement

Empowering patients and caregivers through education fosters understanding of medication purposes, risks, and proper administration, thereby enhancing adherence and willingness to deprescribe[5][14]. Surveys among older adults demonstrate a generally positive attitude toward deprescribing, especially when it is recommended by trusted providers[14][18].

2.5 Technology-Assisted Decision Support

Computerized decision support, embedded in electronic health records, can flag potentially inappropriate medications, duplications, and harmful drug–drug interactions in real time, supporting safer prescribing[16][5][2].

---

3. Challenges and Future Directions

Despite the availability of multiple strategies, consistent implementation in clinical practice remains limited by time constraints, resource limitations, variable reimbursement structures, and cultural inertia among both prescribers and patients[1][5][16][18]. Future directions include refining definitions and measurements of polypharmacy, greater incorporation of artificial intelligence and health IT tools, development and validation of disease-specific deprescribing criteria, and incentive structures for routine medication reviews[2][6][10].

---

4. Conclusion

Polypharmacy in older adults is prevalent globally—with studies reporting rates ranging from 10% to above 80% depending on definition and setting—and is consistently linked to worse clinical outcomes, including ADEs, cognitive and functional decline, falls, and mortality[1][4][15][19][20][3]. Addressing the risks of polypharmacy requires robust, patient-centered, and system-level strategies: regular medication review, judicious application of screening tools, multidisciplinary collaboration, ongoing patient engagement, and technology-assisted support. No single intervention suffices; an adaptive, comprehensive approach customized to the needs and contexts of older adults is required to ensure that drug therapy maximizes benefit and minimizes harm[16][5][2].